SPEECH-PROCESSING-SOLUTI
25.6.2024 09:03:32 CEST | Business Wire | Press release
Philips Speech by Speech Processing Solutions, a globally leading innovator in voice technology, has announced that they are taking their cooperation with Sembly AI further by extending their audio recorder range with another three new products. Each new recorder is designed to cover different consumer needs and is equipped with Sembly vouchers for users to experience Sembly's new AI capabilities with a free trial version.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625566533/en/
Philips VoiceTracer Audio Recorders (Photo: Business Wire)
Excellent audio recording paired with AI technology
"We are delighted to announce that our partnership with Sembly AI opens up new market opportunities by combining the best of both worlds. By providing top-of-the-line audio recorders paired with an AI meeting assistant, we can offer automatic transcriptions, summaries, and action lists for every recording, whether it’s a lecture or a meeting,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions. “Our innovative solutions enable busy professionals to save time and conduct meetings more efficiently than ever,” he adds.
The new Philips VoiceTracer Audio Recorder DVT4115 and DVT6115, designed for students, boast 3MICs for long-distance recording, ideal for capturing lectures and interviews. Sembly can then transcribe and summarize these recordings. The new Philips VoiceTracer DVT8115, equipped with a 360° microphone, is perfect for recording meeting minutes, with Sembly's easy share function to promptly distribute minutes and action steps to team members. These devices are part of a broader Philips product range, designed to meet diverse recording needs.
Sembly AI offers more than just meeting minutes
The Sembly AI tech startup, founded in 2019, has expanded to offer a wide range of features, including automatic transcription with speaker separation, meeting notes, summaries, and action points. One of the newest innovations is that Sembly AI can now also offer professional AI insights into meetings and conversations, enabling efficient collaboration and streamlined decision-making.
“Our latest AI technology seamlessly integrates with Philips products, adding value whether customers are in the office or on the go. Sembly AI now offers much more than just meeting minutes and we are fully committed to offer new AI services in the coming weeks and months,” explains Gil Makleff, CEO and Co-founder of Sembly AI. “We are proud to collaborate with Philips to enhance the customer experience, empowering users to unlock the full potential of their audio recordings and maximize productivity,” he adds.
These new devices join Philips’ existing portfolio of audio recorders and conference microphones, all compatible with Sembly AI’s software. To discover the entire range of Philips & Sembly products, visit: www.voicetracer.com
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
About Sembly AI
Sembly AI is a voice and conversation analytics technology company, focused on bringing the power of natural language processing to professional meeting environments. Sembly’s products can simplify the work life of distributed teams while providing powerful analytics to help teams attend less while getting more done. Sembly AI was founded by CEO Gil Makleff and CPO Artem Koren in 2019. Gil Makleff was CEO of UMT Consulting Group which was acquired by Ernst & Young. Artem Koren was a Senior Manager at Ernst & Young and CTO at Visual Trading Systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625566533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom